Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis
Authors
Keywords
-
Journal
PHARMACOGENOMICS JOURNAL
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-24
DOI
10.1038/s41397-018-0054-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study
- (2017) Ju-E Liu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients
- (2016) Kimie Sai et al. Drug Metabolism and Pharmacokinetics
- Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk
- (2015) Qingtao Hou et al. MEDICINE
- Meta-Analysis of theSLCO1B1c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
- (2015) Ye Dou et al. Annals of Laboratory Medicine
- SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population
- (2015) Michal Vrablík MEDICAL SCIENCE MONITOR
- Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2
- (2014) Marco Ferrari et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy
- (2013) Jacqueline S. Danik et al. AMERICAN HEART JOURNAL
- SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink
- (2013) D F Carr et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions
- (2012) QiPing Feng et al. PHARMACOGENOMICS
- SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia
- (2011) Paulo Caleb Junior Lima Santos et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Cerivastatin, genetic variants, and the risk of rhabdomyolysis
- (2011) Kristin D. Marciante et al. Pharmacogenetics and Genomics
- Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
- (2011) M. Niemi et al. PHARMACOLOGICAL REVIEWS
- Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
- (2010) L A Donnelly et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- PharmGKB very important pharmacogene: SLCO1B1
- (2010) Connie Oshiro et al. Pharmacogenetics and Genomics
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
- (2009) Deepak Voora et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More